Top

Published in:

01-09-2014 | Therapeutic Approaches to Metastatic Colorectal Cancers (R Salazar, Section Editor)

Oxaliplatin Neurotoxicity

Authors: Roser Velasco, Jordi Bruna

Published in: Current Colorectal Cancer Reports | Issue 3/2014

Abstract

Oxaliplatin (OXA) is a first-line agent in the systemic treatment of colorectal cancer (CRC). OXA-induced neuropathy is the most prominent adverse effect, both during and after the completion of chemotherapy. OXA neurotoxicity (OXA-NTX) is a dose-limiting, frequent, and long-lasting adverse event that may compromise therapeutic outcome and the quality-of-life of CRC patients. Increased knowledge of the pathophysiology and clinical profile of this neuropathy is being achieved. Two types of neuropathy are usually observed, and evidence suggests a link between the acute symptoms and the development of chronic NTX. In this paper we review the main advances and the outstanding issues concerning OXA-NTX, for example calcium/magnesium and other drugs in the prophylaxis and treatment of this neuropathy. Recently available and ongoing investigation of pharmacogenomics, clinical and neurophysiological risk factors, and early markers of OXA-NTX are of great value in clinical decision-making, contributing to minimizing the risk of severe neuropathy.

Nekhlyudov L, Aziz NM, Lerro C, et al. Oncologists’ and primary care physicians’ awareness of late and long-term effects of chemotherapy: implications for care of the growing population of survivors. J Oncol Pract. 2014;10(2):e29–36.PubMedCrossRef

2.••

Zedan AH, Hansen TF, Svenningsen AF, et al. Oxaliplatin-induced neuropathy in colorectal cancer: many questions with few answers. Clin Colorectal Cancer. 2013. (In press). This review excellently summarizes the latest evidence concerning oxaliplatin-induced neuropathy, emphasizing the pathophysiologic and pharmacogenomic background.

André T, Boni C, Mounedji-Boudiaf L, et al. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) InvestigatorsOxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–51.PubMedCrossRef

André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–16.PubMedCrossRef

Cassidy J, Clarke S, Díaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008;26(12):2006–12.PubMedCrossRef

Zaniboni A, Meriggi F. The emerging role of oxaliplatin in the treatment of gastric cancer. J Chemother. 2005;17(6):656–62.PubMedCrossRef

Fu S, Kavanagh JJ, Hu W, et al. Clinical application of oxaliplatin in epithelial ovarian cancer. Int J Gynecol Cancer. 2006;16(5):1717–32.PubMedCrossRef

Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Oncol. 2002;29(5 Suppl 15):11–20. Review.PubMedCrossRef

Mas P, Cholvi M, Nigorra M, et al. Oxaliplatin-associated neurotoxicity in clinical practice. Farm Hosp. 2012;36(5):336–42.CrossRef

10.

Park SB, Goldstein D, Lin CS, et al. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol. 2009;27(8):1243–9.PubMedCrossRef

11.

Argyriou AA, Bruna J, Marmiroli P, et al. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol. 2012;82(1):51–77.PubMedCrossRef

12.

Argyriou AA, Cavaletti G, Briani C, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer. 2013;119(2):438–44.PubMedCrossRef

13.••

Velasco R, Bruna J, Briani C, et al. Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. J Neurol Neurosurg Psychiatry. 2014;85(4):392–8. This paper reports clinical and neurophysiological markers that identify patients at greatest risk of developing severe persistent neuropathy as a result of OXA. The authors provide easy-to-use cut-off values for neurophysiological studies to help the clinician stratify patients at mid-treatment.PubMedCrossRef

14.

Lucchetta M, Lonardi S, Bergamo F, et al. Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer. Cancer Chemother Pharmacol. 2012;70(6):899–902.PubMedCrossRef

15.

Petrioli R, Pascucci A, Francini E, et al. Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. Cancer Chemother Pharmacol. 2008;61(1):105–11.PubMedCrossRef

16.

Grolleau F, Gamelin L, Boisdron-Celle M, et al. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol. 2001;85(5):2293–7.PubMed

17.

Park SB, Lin CS, Krishnan AV, et al. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain. 2009;132(Pt 10):2712–23.PubMedCrossRef

18.

Alejandro LM, Behrendt CE, Chen K, et al. Predicting acute and persistent neuropathy associated with oxaliplatin. Am J Clin Oncol. 2013;36(4):331–7.PubMedCentralPubMedCrossRef

19.

Graham MA, Lockwood GF, Greenslade D, et al. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res. 2000;6(4):1205–18.PubMed

20.

Alcindor T, Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol. 2011;18(1):18–25.PubMedCentralPubMedCrossRef

21.

Sakurai M, Egashira N, Kawashiri T, et al. Oxaliplatin-induced neuropathy in the rat: involvement of oxalate in cold hyperalgesia but not mechanical allodynia. Pain. 2009;147(1–3):165–74.PubMedCrossRef

22.

Adelsberger H, Quasthoff S, Grosskreutz J, et al. The chemotherapeutic oxaliplatin alters voltage-gated Na⁺ channel kinetics on rat sensory neurons. Eur J Pharmacol. 2000;406:25–32.PubMedCrossRef

23.••

Park SB, Lin CS, Krishnan AV, et al. Dose effects of oxaliplatin on persistent and transient Na⁺ conductances and the development of neurotoxicity. PLoS One. 2011;6(4):e18469. The authors examined the pathophysiology of acute OXA changes demonstrating that OXA preferentially affects voltage-gated Na currents with transient inactivation kinetics, contributing to knowledge of the mechanisms of OXA-NTX.PubMedCentralPubMedCrossRef

24.

Webster RG, Brain KL, Wilson RH, et al. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol. 2005;146(7):1027–39.PubMedCentralPubMedCrossRef

25.

Armstrong CM, Cota G. Calcium block of Na⁺ channels and its effect on closing rate. Proc Natl Acad Sci U S A. 1999;96(7):4154–7.PubMedCentralPubMedCrossRef

26.

Mogyoros I, Bostock H, Burke D. Mechanisms of paresthesias arising from healthy axons. Muscle Nerve. 2000;23(3):310–20.PubMedCrossRef

27.

Park SB, Lin CS, Krishnan AV, et al. Oxaliplatin-induced Lhermitte’s phenomenon as a manifestation of severe generalized neurotoxicity. Oncology. 2009;77(6):342–8.PubMedCrossRef

28.

Velasco R, Bruna J. Chemotherapy-induced peripheral neuropathy: an unresolved issue. Neurologia. 2010;25(2):116–31. Review.PubMedCrossRef

29.

Sereno M, Gutiérrez-Gutiérrez G, Gómez-Raposo C, et al. Oxaliplatin induced-neuropathy in digestive tumors. Crit Rev Oncol Hematol. 2014;89(1):166–78.PubMedCrossRef

30.

Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol. 2012;14(4):iv45–54.PubMedCentralPubMed

31.

Pietrangeli A, Leandri M, Terzoli E, et al. Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol. 2006;56(1):13–6.PubMedCrossRef

32.

Vatandoust S, Joshi R, Pittman KB, et al. A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer. Support Care Cancer. 2014;22(2):513–8.PubMedCrossRef

33.

Kidwell KM, Yothers G, Ganz PA, et al. Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. Cancer. 2012;118(22):5614–22.PubMedCentralPubMedCrossRef

34.••

Mols F, Beijers T, Lemmens V, et al. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol. 2013;31(21):2699–707. This large study including more than one thousand CRC patients revealed long-lasting symptoms and signs as a result of OXA-NTX by using the CIPN20 EORTC questionnaire, highlighting the putative irreversibility of this adverse event.PubMedCrossRef

35.

Park SB, Lin CS, Krishnan AV, et al. Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist. 2011;16(5):708–16.PubMedCentralPubMedCrossRef

36.

Gornet JM, Savier E, Lokiec F, et al. Exacerbation of oxaliplatin neurosensory toxicity following surgery. Ann Oncol. 2002;13:1315–8.PubMedCrossRef

37.

Tofthagen C. Surviving chemotherapy for colon cancer and living with the consequences. J Palliat Med. 2010;13(11):1389–91.PubMedCrossRef

38.

Tofthagen C, Donovan KA, Morgan MA, et al. Oxaliplatin-induced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors. Support Care Cancer. 2013;21(12):3307–13.PubMedCrossRef

39.

Bennett BK, Park SB, Lin CS, et al. Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer. 2012;20(11):2959–67.PubMedCrossRef

40.

National Cancer Institute: Common Terminology Criteria of Adverse Events Version 4.0. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf

41.

Postma TJ, Heimans JJ. Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol. 2000;11(5):509–13. Review.PubMedCrossRef

42.

Hughes R. NCI-CTC vs TNS: which tool is better for grading the severity of chemotherapy-induced peripheral neuropathy? Nat Clin Pract Neurol. 2008;4:68–9.PubMedCrossRef

43.

Frigeni B, Piatti M, Lanzani F, et al. Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale. J Peripher Nerv Syst. 2011;16:228–36.PubMedCrossRef

44.

Cornblath DR, Chaudhry V, Carter K, et al. Total neuropathy score: validation and reliability study. Neurology. 1999;53:1660–4.PubMedCrossRef

45.

Cavaletti G, Frigeni B, Lanzani F, et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst. 2007;12:210–5.PubMedCrossRef

46.••

Cavaletti G, Cornblath DR, Merkies IS, et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol. 2013;24(2):454–62. Large multicenter study including 105 patients affected by persistent OXA-NTX evaluating the psychometric properties of several tools commonly used for assessment of this adverse event.PubMedCentralPubMedCrossRef

47.

Lehky TJ, Leonard GD, Wilson RH, et al. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve. 2004;29:387–92.PubMedCrossRef

48.

Wilson RH, Lehky T, Thomas RR, et al. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol. 2002;20(7):1767–74.PubMedCrossRef

49.

Alberti P, Rossi E, Cornblath DR, et al. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol. 2014;25(1):257–64.PubMedCrossRef

50.

Land SR, Kopec JA, Cecchini RS, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III Colon Cancer: NSABP C-07. J ClinOncol. 2007;25:2205–11.CrossRef

51.

Postma TJ, Aaronson NK, Heimans JJ, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer. 2005;41(8):1135–9.PubMedCrossRef

52.

Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P, Seisler D, Qamar R, Lewis GC, Grothey A. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol. (In press).

53.

Tofthagen CS, McMillan SC, Kip KE. Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool. Cancer Nurs. 2011;34(4):E10–20.PubMedCrossRef

54.

Binda D, Vanhoutte EK, Cavaletti G, et al. Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS). Eur J Cancer. 2013;49(13):2910–8.PubMedCrossRef

55.

Krishnan AV, Goldstein D, Friedlander M, et al. Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve. 2005;32:51–60.PubMedCrossRef

56.

Attal N, Bouhassira D, Gautron M, et al. Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study. Pain. 2009;144:245–52.PubMedCrossRef

57.

Krøigård T, Schrøder HD, Qvortrup C, et al. Characterization and diagnostic evaluation of chronic polyneuropathies induced by oxaliplatin and docetaxel comparing skin biopsy to quantitative sensory testing and nerve conduction studies. Eur J Neurol. 2014;21(4):623–9.PubMedCrossRef

58.

McHugh JC, Tryfonopoulos D, Fennelly D, et al. Electroclinical biomarkers of early peripheral neurotoxicity from oxaliplatin. Eur J Cancer Care (Engl). 2012;21(6):782–9.CrossRef

59.

Baek KK, Lee J, Park SH, et al. Oxaliplatin-induced chronic peripheral neurotoxicity: a prospective analysis in patients with colorectal cancer. Cancer Res Treat. 2010;42(4):185–90.PubMedCentralPubMedCrossRef

60.

Argyriou AA, Velasco R, Briani C, et al. Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. Ann Oncol. 2012;23(12):3116–22.PubMedCrossRef

61.

Storey DJ, Sakala M, McLean CM, et al. Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy? Ann Oncol. 2010;21(8):1657–61.PubMedCrossRef

62.

Arkenau HT, Arnold D, Cassidy J, et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol. 2008;26(36):5910–7.PubMedCrossRef

63.

Gamelin L, Capitain O, Morel A, et al. Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res. 2007;13(21):6359–68.PubMedCrossRef

64.

Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006;24(25):4085–91.PubMedCrossRef

65.

Vincenzi B, Frezza AM, Schiavon G, et al. Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. Support Care Cancer. 2013;21(5):1313–9.PubMedCrossRef

66.

Chua W, Kho PS, Moore MM, et al. Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. Crit Rev Oncol Hematol. 2011;79(3):224–50.PubMedCrossRef

67.

Boyette-Davis JA, Eng C, Wang XS, et al. Subclinical peripheral neuropathy is a common finding in colorectal cancer patients prior to chemotherapy. Clin Cancer Res. 2012;18(11):3180–7.PubMedCentralPubMedCrossRef

68.

Ramanathan RK, Rothenberg ML, de Gramont A, et al. Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies. Ann Oncol. 2010;21(4):754–8.PubMedCrossRef

69.

Uwah AN, Ackler J, Leighton Jr JC, et al. The effect of diabetes on oxaliplatin-induced peripheral neuropathy. Clin Colorectal Cancer. 2012;11:275–9.PubMedCrossRef

70.

Takimoto CH, Graham MA, Lockwood G, et al. Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res. 2007;13(16):4832–9.PubMedCrossRef

71.

Hsu TW, Chen FA, Yao YH, et al. Creatinine clearance rate and nerve conduction velocity are effective in objectively assessing oxaliplatin-neuropathy in patients with colorectal carcinoma. Hepatogastroenterology. 2012;59(117):1441–5.PubMed

72.

Cavaletti G, Alberti P, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol. 2011;12(12):1151–61.PubMedCrossRef

73.

Kweekel DM, Gelderblom H, Guchelaar HJ. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev. 2005;31(2):90–105.PubMedCrossRef

74.

Peng Z, Wang Q, Gao J, et al. Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-analysis. Cancer Chemother Pharmacol. 2013;72(2):305–14.PubMedCrossRef

75.

Kanai M, Yoshioka A, Tanaka S, et al. Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy. Cancer Epidemiol. 2010;34(2):189–93.PubMedCrossRef

76.

Argyriou AA, Antonacopoulou AG, Scopa CD, et al. Liability of the voltage-gated sodium channel gene SCN2A R19K polymorphism to oxaliplatin-induced peripheral neuropathy. Oncology. 2009;77(3–4):254–6.PubMedCrossRef

77.

Basso M, Modoni A, Spada D, et al. Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity. Cancer Chemother Pharmacol. 2011;67(5):1179–87.PubMedCrossRef

78.

Argyriou AA, Cavaletti G, Antonacopoulou A, et al. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study. Cancer. 2013;119(19):3570–7.PubMed

79.

Cecchin E, D’Andrea M, Lonardi S, et al. A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5fluorouraci/leucovorin/oxaliplatin (FOLFOX4) regimen. Pharmacogenomics J. 2013;13(5):403–9.PubMedCrossRef

80.

Custodio A, Moreno-Rubio J, Aparicio J, et al. Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study. Ann Oncol. 2014;25(2):398–403.PubMedCrossRef

81.

Bhushan S, McLeod H, Walko CM. Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer. Clin Colorectal Cancer. 2009;8(1):15–21.PubMedCrossRef

82.

Antonacopoulou AG, Argyriou AA, Scopa CD, et al. Integrin beta-3 L33P: a new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy? Eur J Neurol. 2010;17(7):963–8.PubMedCrossRef

83.

Velasco R, Petit J, Clapés V, et al. Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients. J Peripher Nerv Syst. 2010;15(1):17–25.PubMedCrossRef

84.

Park SB, Lin CS, Kiernan MC. Nerve excitability assessment in chemotherapy-induced neurotoxicity. J Vis Exp. 2012; 26: (62).

85.

Townsend AR, Bishnoi S, Broadbridge V, et al. Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy. Am J Clin Oncol. 2013;36(1):49–52.PubMedCrossRef

86.

Tonini G, Imperatori M, Vincenzi B, et al. Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer. J Exp Clin Cancer Res. 2013;32(1):92.PubMedCentralPubMedCrossRef

87.

Maindrault-Goebel F, Tournigand C, André T, et al. Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann Oncol. 2004;15(8):1210–4.PubMedCrossRef

88.

de Gramont A, Cervantes A, Andre T. OPTIMOX study: FOL-FOX7/LV5FU2 compared to FOLFOX4 in patients with advanced colorectal cancer. J Clin Oncol. 2004;22:3525.

89.

Adams RA, Meade AM, Seymour MT, et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol. 2011;12(7):642–53.PubMedCentralPubMedCrossRef

90.

Hochster H, Grothey A, Hart L, et al. Improved time to treatment failure with an intermittent oxaliplatin strategy: results of the CONcePT trial. Ann Oncol. 2014. (In Press)

91.

Kono T, Satomi M, Asama T, et al. Cetuximab-induced hypomagnesaemia aggravates peripheral sensory neurotoxicity caused by oxaliplatin. J Gastrointest Oncol. 2010;1(2):97–101.PubMedCentralPubMed

92.

Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12):1539–44.PubMedCrossRef

93.

Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol. 2008;26(21):3523–9.PubMedCrossRef

94.

Wen F, Zhou Y, Wang W, et al. Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: a meta-analysis. Ann Oncol. 2013;24(1):171–8.PubMedCrossRef

95.

Ao R, Wang YH, Li RW, et al. Effects of calcium and magnesium on acute and chronic neurotoxicity caused by oxaliplatin: A meta-analysis. Exp Ther Med. 2012;4(5):933–7.PubMedCentralPubMed

96.

Xu XT, Dai ZH, Xu Q, et al. Safety and efficacy of calcium and magnesium infusions in the chemoprevention of oxaliplatin-induced sensory neuropathy in gastrointestinal cancers. J Dig Dis. 2013;14(6):288–98.PubMedCrossRef

97.

Wu Z, Ouyang J, He Z, et al. Infusion of calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in colorectal cancer: a systematic review and meta-analysis. Eur J Cancer. 2012;48(12):1791–8.PubMedCrossRef

98.

Pace A, Giannarelli D, Galiè E, et al. Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. Neurology. 2010;74(9):762–6.PubMedCrossRef

99.

Afonseca SO, Cruz FM, Cubero Dde I, et al. Vitamin E for prevention of oxaliplatin-induced peripheral neuropathy: a pilot randomized clinical trial. Sao Paulo Med J. 2013;131(1):35–8.PubMedCrossRef

100.

Kottschade LA, Sloan JA, Mazurczak MA, et al. The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Support Care Cancer. 2011;19(11):1769–77.PubMedCentralPubMedCrossRef

101.

Durand JP, Deplanque G, Montheil V, et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2012;23(1):200–5.PubMedCrossRef

102.••

Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309(13):1359–67. First phase III trial to demonstrate the effectiveness of symptomatic treatment in a setting of persistent painful chemotherapy-induced peripheral neuropathy, especially OXA-induced.PubMedCentralPubMedCrossRef

103.

Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9(2):105–21.PubMedCrossRef

104.

André T, Iveson T, Labianca R, et al. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: prospective combined analysis of Phase III trials investigating duration of adjuvant therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for patients with Stage III colon cancer: trial design and current status. Curr Colorectal Cancer Rep. 2013;9:261–9.PubMedCentralPubMedCrossRef

Title: Oxaliplatin Neurotoxicity
Authors: Roser Velasco
Jordi Bruna
Publication date: 01-09-2014
Publisher: Springer US
Published in: Current Colorectal Cancer Reports / Issue 3/2014
Print ISSN: 1556-3790
Electronic ISSN: 1556-3804
DOI: https://doi.org/10.1007/s11888-014-0230-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

New Targets and New Drug Development in Colorectal Cancer

Update on the Colon Health and Life-Long Exercise Change Trial: A Phase III Study of the Impact of an Exercise Program on Disease-Free Survival in Colon Cancer Survivors

Accuracy of Predefined Hypotheses in Colon Cancer Adjuvant Phase III Trials: Observations and Recommendations

Prognostic Impact of Deficient DNA Mismatch Repair and KRAS and BRAF V600E Mutations in Patients with Lymph-Node-Positive Colon Cancer

Erratum to: Do We Need another Antiangiogenesis Agent for Colorectal Cancer: are Bevacizumab and Aflibercept the Same?

Clinical End Points and Relevant Clinical Benefits in Advanced Colorectal Cancer Trials

Keynote webinar | Spotlight on antibody–drug conjugates in cancer